Financial - Capital Markets
Compare Stocks
4 / 10Stock Comparison
NMR vs GS vs MS vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
Financial - Capital Markets
Financial - Capital Markets
Banks - Diversified
NMR vs GS vs MS vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Financial - Capital Markets | Financial - Capital Markets | Financial - Capital Markets | Banks - Diversified |
| Market Cap | $22.85B | $287.62B | $302.59B | $825.89B |
| Revenue (TTM) | $4.76T | $126.85B | $103.14B | $270.79B |
| Net Income (TTM) | $370.05B | $16.67B | $16.18B | $58.03B |
| Gross Margin | 45.6% | 41.1% | 55.6% | 58.6% |
| Operating Margin | 11.3% | 14.5% | 17.1% | 27.7% |
| Forward P/E | 9.7x | 15.6x | 16.0x | 13.8x |
| Total Debt | $17.30T | $616.93B | $360.49B | $751.15B |
| Cash & Equiv. | $4.30T | $182.09B | $75.74B | $469.32B |
NMR vs GS vs MS vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Nomura Holdings, In… (NMR) | 100 | 185.8 | +85.8% |
| The Goldman Sachs G… (GS) | 100 | 471.2 | +371.2% |
| Morgan Stanley (MS) | 100 | 430.3 | +330.3% |
| JPMorgan Chase & Co. (JPM) | 100 | 314.8 | +214.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NMR vs GS vs MS vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NMR is the #2 pick in this set and the best alternative if valuation efficiency and defensive is your priority.
- PEG 0.49 vs MS's 1.80
- Beta 1.32, yield 4.8%, current ratio 1.43x
- Lower P/E (9.7x vs 13.8x), PEG 0.49 vs 1.06
- 4.8% yield, 3-year raise streak, vs JPM's 1.7%
GS carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 17.0%, EPS growth 77.3%
- 17.0% NII/revenue growth vs NMR's 5.6%
- Efficiency ratio 0.3% vs MS's 0.4% (lower = leaner)
- +70.6% vs JPM's +25.2%
MS is the clearest fit if your priority is long-term compounding.
- 7.3% 10Y total return vs GS's 5.3%
JPM is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 14 yrs, beta 1.00, yield 1.7%
- Lower volatility, beta 1.00, current ratio 0.65x
- NIM 2.3% vs GS's 0.5%
- Beta 1.00 vs GS's 1.47, lower leverage
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 17.0% NII/revenue growth vs NMR's 5.6% | |
| Value | Lower P/E (9.7x vs 13.8x), PEG 0.49 vs 1.06 | |
| Quality / Margins | Efficiency ratio 0.3% vs MS's 0.4% (lower = leaner) | |
| Stability / Safety | Beta 1.00 vs GS's 1.47, lower leverage | |
| Dividends | 4.8% yield, 3-year raise streak, vs JPM's 1.7% | |
| Momentum (1Y) | +70.6% vs JPM's +25.2% | |
| Efficiency (ROA) | Efficiency ratio 0.3% vs MS's 0.4% |
NMR vs GS vs MS vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
NMR vs GS vs MS vs JPM — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
JPM leads in 2 of 6 categories
NMR leads 1 • GS leads 1 • MS leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
NMR is the larger business by revenue, generating $4.76T annually — 46.1x MS's $103.1B. JPM is the more profitable business, keeping 21.6% of every revenue dollar as net income compared to NMR's 7.6%.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $4.76T | $126.9B | $103.1B | $270.8B |
| EBITDAEarnings before interest/tax | $533.0B | $23.4B | $26.3B | $81.3B |
| Net IncomeAfter-tax profit | $370.1B | $16.7B | $16.2B | $58.0B |
| Free Cash FlowCash after capex | $0 | $15.8B | -$6.7B | -$119.7B |
| Gross MarginGross profit ÷ Revenue | +45.6% | +41.1% | +55.6% | +58.6% |
| Operating MarginEBIT ÷ Revenue | +11.3% | +14.5% | +17.1% | +27.7% |
| Net MarginNet income ÷ Revenue | +7.6% | +11.3% | +13.0% | +21.6% |
| FCF MarginFCF ÷ Revenue | -25.2% | -12.1% | -2.0% | -15.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -5.5% | +45.8% | +48.9% | +16.0% |
Valuation Metrics
NMR leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
At 10.4x trailing earnings, NMR trades at a 57% valuation discount to MS's 23.9x P/E. Adjusting for growth (PEG ratio), NMR offers better value at 0.53x vs MS's 2.69x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $22.9B | $287.6B | $302.6B | $825.9B |
| Enterprise ValueMkt cap + debt − cash | $106.0B | $722.5B | $587.3B | $1.11T |
| Trailing P/EPrice ÷ TTM EPS | 10.40x | 22.84x | 23.92x | 15.51x |
| Forward P/EPrice ÷ next-FY EPS est. | 9.69x | 15.64x | 16.01x | 13.79x |
| PEG RatioP/E ÷ EPS growth rate | 0.53x | 1.63x | 2.69x | 1.19x |
| EV / EBITDAEnterprise value multiple | 27.25x | 34.75x | 25.81x | 13.34x |
| Price / SalesMarket cap ÷ Revenue | 0.75x | 2.27x | 2.93x | 3.05x |
| Price / BookPrice ÷ Book value/share | 0.98x | 2.53x | 2.91x | 2.56x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
Profitability & Efficiency
JPM leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 16.1% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $10 for NMR. JPM carries lower financial leverage with a 2.18x debt-to-equity ratio, signaling a more conservative balance sheet compared to GS's 5.06x. On the Piotroski fundamental quality scale (0–9), NMR scores 5/9 vs GS's 4/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +10.2% | +12.6% | +14.6% | +16.1% |
| ROA (TTM)Return on assets | +0.6% | +0.9% | +1.2% | +1.3% |
| ROICReturn on invested capital | +1.4% | +1.9% | +2.9% | +5.4% |
| ROCEReturn on capital employed | +2.4% | +3.6% | +3.8% | +8.2% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 | 5 | 5 |
| Debt / EquityFinancial leverage | 4.49x | 5.06x | 3.42x | 2.18x |
| Net DebtTotal debt minus cash | $13.00T | $434.8B | $284.7B | $281.8B |
| Cash & Equiv.Liquid assets | $4.30T | $182.1B | $75.7B | $469.3B |
| Total DebtShort + long-term debt | $17.30T | $616.9B | $360.5B | $751.1B |
| Interest CoverageEBIT ÷ Interest expense | 0.20x | 0.31x | 0.44x | 0.74x |
Total Returns (Dividends Reinvested)
GS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GS five years ago would be worth $26,440 today (with dividends reinvested), compared to $16,851 for NMR. Over the past 12 months, GS leads with a +70.6% total return vs JPM's +25.2%. The 3-year compound annual growth rate (CAGR) favors GS at 43.5% vs JPM's 32.9% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -6.3% | +1.8% | +5.7% | -5.0% |
| 1-Year ReturnPast 12 months | +47.1% | +70.6% | +63.0% | +25.2% |
| 3-Year ReturnCumulative with dividends | +145.2% | +195.2% | +138.4% | +134.6% |
| 5-Year ReturnCumulative with dividends | +68.5% | +164.4% | +136.2% | +104.3% |
| 10-Year ReturnCumulative with dividends | +141.5% | +534.3% | +732.3% | +461.3% |
| CAGR (3Y)Annualised 3-year return | +34.8% | +43.5% | +33.6% | +32.9% |
Risk & Volatility
Evenly matched — MS and JPM each lead in 1 of 2 comparable metrics.
Risk & Volatility
JPM is the less volatile stock with a 1.00 beta — it tends to amplify market swings less than GS's 1.47 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MS currently trades 97.6% from its 52-week high vs NMR's 82.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.32x | 1.47x | 1.37x | 1.00x |
| 52-Week HighHighest price in past year | $9.58 | $984.70 | $194.83 | $337.25 |
| 52-Week LowLowest price in past year | $5.48 | $547.74 | $118.20 | $248.83 |
| % of 52W HighCurrent price vs 52-week peak | +82.6% | +94.0% | +97.6% | +90.8% |
| RSI (14)Momentum oscillator 0–100 | 51.7 | 59.5 | 66.0 | 59.4 |
| Avg Volume (50D)Average daily shares traded | 2.1M | 2.0M | 5.4M | 8.3M |
Analyst Outlook
Evenly matched — NMR and JPM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: NMR as "Hold", GS as "Hold", MS as "Buy", JPM as "Buy". Consensus price targets imply 10.6% upside for JPM (target: $339) vs -26.8% for NMR (target: $6). For income investors, NMR offers the higher dividend yield at 4.77% vs GS's 1.46%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $5.79 | $995.89 | $205.75 | $338.78 |
| # AnalystsCovering analysts | 9 | 55 | 52 | 61 |
| Dividend YieldAnnual dividend ÷ price | +4.8% | +1.5% | +2.0% | +1.7% |
| Dividend StreakConsecutive years of raises | 3 | 12 | 11 | 14 |
| Dividend / ShareAnnual DPS | $59.06 | $13.48 | $3.81 | $5.13 |
| Buyback YieldShare repurchases ÷ mkt cap | +2.8% | +3.5% | +1.4% | +3.5% |
JPM leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). NMR leads in 1 (Valuation Metrics). 2 tied.
NMR vs GS vs MS vs JPM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NMR or GS or MS or JPM a better buy right now?
For growth investors, The Goldman Sachs Group, Inc.
(GS) is the stronger pick with 17. 0% revenue growth year-over-year, versus 5. 6% for Nomura Holdings, Inc. (NMR). Nomura Holdings, Inc. (NMR) offers the better valuation at 10. 4x trailing P/E (9. 7x forward), making it the more compelling value choice. Analysts rate Morgan Stanley (MS) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NMR or GS or MS or JPM?
On trailing P/E, Nomura Holdings, Inc.
(NMR) is the cheapest at 10. 4x versus Morgan Stanley at 23. 9x. On forward P/E, Nomura Holdings, Inc. is actually cheaper at 9. 7x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Nomura Holdings, Inc. wins at 0. 49x versus Morgan Stanley's 1. 80x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — NMR or GS or MS or JPM?
Over the past 5 years, The Goldman Sachs Group, Inc.
(GS) delivered a total return of +164. 4%, compared to +68. 5% for Nomura Holdings, Inc. (NMR). Over 10 years, the gap is even starker: MS returned +732. 3% versus NMR's +141. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NMR or GS or MS or JPM?
By beta (market sensitivity over 5 years), JPMorgan Chase & Co.
(JPM) is the lower-risk stock at 1. 00β versus The Goldman Sachs Group, Inc. 's 1. 47β — meaning GS is approximately 46% more volatile than JPM relative to the S&P 500. On balance sheet safety, JPMorgan Chase & Co. (JPM) carries a lower debt/equity ratio of 2% versus 5% for The Goldman Sachs Group, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — NMR or GS or MS or JPM?
By revenue growth (latest reported year), The Goldman Sachs Group, Inc.
(GS) is pulling ahead at 17. 0% versus 5. 6% for Nomura Holdings, Inc. (NMR). On earnings-per-share growth, the picture is similar: The Goldman Sachs Group, Inc. grew EPS 77. 3% year-over-year, compared to 7. 2% for Nomura Holdings, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NMR or GS or MS or JPM?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 21. 6% net margin versus 7. 6% for Nomura Holdings, Inc. — meaning it keeps 21. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 27. 7% versus 11. 3% for NMR. At the gross margin level — before operating expenses — JPM leads at 58. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NMR or GS or MS or JPM more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Nomura Holdings, Inc. (NMR) is the more undervalued stock at a PEG of 0. 49x versus Morgan Stanley's 1. 80x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Nomura Holdings, Inc. (NMR) trades at 9. 7x forward P/E versus 16. 0x for Morgan Stanley — 6. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for JPM: 10. 6% to $338. 78.
08Which pays a better dividend — NMR or GS or MS or JPM?
All stocks in this comparison pay dividends.
Nomura Holdings, Inc. (NMR) offers the highest yield at 4. 8%, versus 1. 5% for The Goldman Sachs Group, Inc. (GS).
09Is NMR or GS or MS or JPM better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 00), 1. 7% yield, +461. 3% 10Y return). Both have compounded well over 10 years (JPM: +461. 3%, NMR: +141. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NMR and GS and MS and JPM?
Both stocks operate in the Financial Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: NMR is a mid-cap deep-value stock; GS is a large-cap high-growth stock; MS is a large-cap high-growth stock; JPM is a large-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.